Incidence of internal mammary lymph nodes with silicone breast implants at MR imaging after oncoplastic surgery Journal Article
| Authors: | Sutton, E. J.; Watson, E. J.; Gibbons, G.; Goldman, D. A.; Moskowitz, C. S.; Jochelson, M. S.; Dershaw, D. D.; Morris, E. A. |
| Article Title: | Incidence of internal mammary lymph nodes with silicone breast implants at MR imaging after oncoplastic surgery |
| Abstract: | Purpose: To assess the incidence of benign and malignant internal mammary lymph nodes (IMLNs) at magnetic resonance (MR) imaging among women with a history of treated breast cancer and silicone implant reconstruction. Materials and Methods: The institutional review board approved this HIPAA-compliant retrospective study and waived informed consent. Women were identified who (a) had breast cancer, (b) underwent silicone implant oncoplastic surgery, and (c) underwent postoperative implant-protocol MR imaging with or without positron emission tomography (PET)/computed tomography (CT) between 2000 and 2013. The largest IMLNs were measured. A benign IMLN was pathologically proven or defined as showing 1 year of imaging stability and/or no clinical evidence of disease. Malignant IMLNs were pathologically proven. Incidence of IMLN and positive predictive value (PPV) were calculated on a perpatient level by using proportions and exact 95% confidence intervals (CIs). The Wilcoxon rank sum test was used to assess the difference in axis size. Results: In total, 923 women with breast cancer and silicone implants were included (median age, 46 years; range, 22-89 years). The median time between reconstructive surgery and first MR imaging examination was 49 months (range, 5-513 months). Of the 923 women, 347 (37.6%) had IMLNs at MR imaging. Median short-and long-axis measurements were 0.40 cm (range, 0.20-1.70 cm) and 0.70 cm (range, 0.30-1.90 cm), respectively. Two hundred seven of 923 patients (22.4%) had adequate follow-up; only one of the 207 IMLNs was malignant, with a PPV of 0.005 (95% CI: 0.000, 0.027). Fifty-eight of 923 patients (6.3%) had undergone PET/CT; of these, 39 (67.2%) had IMLN at MR imaging. Twelve of the 58 patients (20.7%) with adequate follow-up had fluorine 18 fluorodeoxyglucose- avid IMLN, with a median standardized uptake value of 2.30 (range, 1.20-6.10). Only one of the 12 of the fluorodeoxyglucose-avid IMLNs was malignant, with a PPV of 0.083 (95% CI: 0.002, 0.385). Conclusion: IMLNs identified at implant-protocol breast MR imaging after oncoplastic surgery for breast cancer are overwhelmingly more likely to be benign than malignant. Imaging follow-up instead of immediate metastatic work-up may be warranted. © 2015 RSNA. |
| Keywords: | adult; aged; cancer surgery; major clinical study; plastic surgery; postoperative care; nuclear magnetic resonance imaging; follow up; lymph node metastasis; breast cancer; retrospective study; lymph node; partial mastectomy; fluorodeoxyglucose f 18; computer assisted emission tomography; breast surgery; predictive value; pet scanner; nuclear magnetic resonance scanner; radiological procedures; very elderly; silicone breast implant; human; female; priority journal; article; internal mammary lymph node |
| Journal Title: | Radiology |
| Volume: | 277 |
| Issue: | 2 |
| ISSN: | 0033-8419 |
| Publisher: | Radiological Society of North America, Inc. |
| Date Published: | 2015-11-01 |
| Start Page: | 381 |
| End Page: | 387 |
| Language: | English |
| DOI: | 10.1148/radiol.2015142717 |
| PROVIDER: | scopus |
| PUBMED: | 26098457 |
| PMCID: | PMC4976465 |
| DOI/URL: | |
| Notes: | Export Date: 2 December 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work